One Cup a Day Keeps Atrial Fibrillation Away

Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial.

JAMA โ€ข โ€ข Clinical Trial โ€ข Moderately Relevant
๐Ÿค–

AI Summary

This intriguing clinical trial challenges conventional medical assumptions about caffeine consumption in patients with atrial fibrillation (AF). Researchers conducted a randomized study with 200 patients investigating the effects of coffee consumption versus complete caffeine abstinence over a six-month period. Surprisingly, the results revealed that patients who consumed at least one cup of caffeinated coffee daily experienced 39% less recurrence of atrial fibrillation compared to those who completely avoided coffee.

The study, conducted across hospitals in the US, Canada, and Australia, tracked patients after electrical cardioversion, a procedure to restore normal heart rhythm. Participants drinking an average of one cup of coffee per day showed significantly lower rates of heart rhythm disruptions, with AF or atrial flutter recurring in only 47% of the coffee consumption group compared to 64% in the abstinence group. Importantly, the research found no significant difference in adverse events between the two groups, suggesting that moderate coffee consumption might actually be beneficial for patients with heart rhythm disorders.

While this research doesn't directly relate to cannabis, it highlights the complex interactions between dietary habits and medical conditions. The study demonstrates how carefully controlled clinical trials can challenge existing medical assumptions and provide nuanced insights into lifestyle interventions. Medical professionals and patients alike are encouraged to consider individualized approaches to health management, recognizing that blanket recommendations may not always be the most effective strategy.

๐Ÿ“„ Original Abstract

Conventional wisdom holds that caffeinated coffee is proarrhythmic. Coffee is the most commonly consumed caffeinated beverage in the US, and a randomized trial assessing caffeinated coffee consumption in patients with atrial fibrillation (AF) has not previously been performed. To determine the effect of caffeinated coffee consumption compared with abstinence from coffee and caffeine on recurrent AF. This was a prospective, open-label, randomized clinical trial enrolling 200 current or previous (within past 5 years) coffee-drinking adults with persistent AF, or atrial flutter with a history of AF, planned for electrical cardioversion from 5 hospitals in the US, Canada, and Australia between November 2021 and December 2024. The date of final follow-up was June 5, 2025. Patients were randomized in a 1:1 ratio to regular caffeinated coffee consumption vs coffee and caffeine abstinence for 6 months. Patients in the coffee consumption group were encouraged to drink at least 1 cup of caffeinated coffee daily. Patients in the abstinence group were encouraged to completely abstain from both caffeinated and decaffeinated coffee and other caffeine-containing products. The primary end point was clinically detected recurrence of AF or atrial flutter over 6 months. Two hundred patients (mean [SD] age, 69 [11] years; 71% male) were randomized to caffeinated coffee consumption (n = 100) or coffee abstinence (n = 100). Baseline coffee intake was 7 cups (IQR, 7-18) per week in both groups. During follow-up, coffee intake in the consumption and abstinence groups was 7 (IQR, 6-11) and 0 (IQR, 0-2) cups per week, respectively, resulting in a between-group difference of 7 cups (95% CI, 7-7) per week. In the primary analysis, AF or atrial flutter recurrence was less in the coffee consumption (47%) than the coffee abstinence (64%) group, resulting in a 39% lower hazard of recurrence (hazard ratio, 0.61 [95% CI, 0.42-0.89]; P = .01). A comparable benefit of coffee consumption was observed with AF recurrence only. There was no significant difference in adverse events. In this clinical trial of coffee drinkers after successful cardioversion, allocation to consumption of caffeinated coffee averaging 1 cup a day was associated with less recurrence of AF or atrial flutter compared with abstinence from coffee and caffeinated products. ClinicalTrials.gov Identifier: NCT05121519.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.